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Abstract: Tumor as source of tumor associated antigens (TAA) and sentinel lymph node 
(SLN) conﬁ  gure the ﬁ  rst interaction between the malignant disease and the patient’s immune 
system. As consequence of this interaction, a local immune response is elicited inside the SLN. 
Tumor’s cytokines reach the SLN conditioning its cellular microenvironment to produce local 
permissive immune responses. This local tolerogenic immunity is decisional because it starts 
a systemic also permissive immunity. The tumor progresses.
To counteract this mechanism, we have designed a medical procedure to create an immu-
notherapeutic site (ITS) that reproduces, distantly from the tumor, a TAA source and a draining 
lymph node but with a cellular microenvironment conditioned to promote local protective instead 
of permissive immune responses. Due to ITS decisional role, this local protective immunity 
starts a systemic anti-tumoral immune response.
In progressive ovarian cancer, we tested an ITS using the autologous thermostable 
hemoderivative-cancer vaccine as TAA source and granulocyte macrophage-colony stimulant 
factor plus etoposide, injected both at the vaccination site, as conditioner of the draining lymph 
node cellularity. The immunophenotyping of lymph node cell populations showed that ITS 
acquired a locally protective immune proﬁ  le T-regulatory-cells/activated-antigen presenting-
cells and systemically increased the antiprogressive effect of the tested vaccine.
Keywords: autologous vaccine, ovarian cancer, cancer vaccine, cancer immunotherapy, 
immunotherapy adjuvants
Introduction
In cancer disease, a locoregional immune microenvironment constituted by the tumor 
as source of tumor associated antigens (TAA) and the sentinel lymph node (SLN) 
as the ﬁ  rst reactive draining site for TAA can be deﬁ  ned. During cancer develop-
ment, a locoregional immune response is elicited at this microenvironment and it 
can potentially be permissive or protective, immunologically known as tolerogenic 
or immunogenic. This locoregional immune response is decisional because it starts 
a systemic immune response with the same conﬁ  guration as its own: tolerogenic or 
immunogenic. In cancer patients, tumor invasion and dissemination evidence the 
predominance of tolerogenic over immunogenic immune responses, either local 
and/or systemic. Strong data supports that the tumor induces an immunomodulation 
of SLN, conditioning a tolerogenic locoregional immune response that allows lymph 
node metastatic invasion and starts a systemic immune response of tumor tolerance 
permitting tumor dissemination (Cochran et al 2006).
The therapeutic cancer vaccines can be considered as a medical procedure reproduc-
ing the above referred locoregional immune microenvironment of malignant tumors 
but without the tumor-induced immuno-modulative tolerogenic mechanism. In this Biologics: Targets & Therapy 2007:1(2) 174
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case, the vaccination site is the source of TAA included in 
the vaccine and the SLN is the draining lymph node of the 
vaccination site known as sentinel immunized node (SIN). 
Like in tumor disease, the vaccine locoregional immune 
response can express tolerogenic and/or protective activity 
starting the corresponding systemic immune response (Disis 
et al 1996).
The goal of cancer vaccines is to elicit a protective 
systemic immune response. Therefore, the design of vac-
cine adjuvants addressed to switch the vaccine locoregional 
immune response from tolerogenic to protective must be 
investigated as a strategy for starting optimized systemic 
anti-tumoral vaccine effects. In tumors and cancer vaccines, 
several modulators of the locoregional immune microenvi-
ronment that condition the anti-tumoral immune responses 
have been identiﬁ  ed. We have selected two of them to be 
studied taking in account their known mechanism of action 
and their safety proven in their extensive clinical use.
Granulocyte-macrophage colony-stimulating factor 
(GM-CSF) is a potent immune stimulant when admin-
istered with different vaccines at the vaccination site. In 
addition, intratumoral GM-CSF induces local and remote 
antitumoral effects. The mechanism of action of GM-CSF 
resides in its ability to act locally, stimulating the prolifera-
tion and maturation of professional antigen-presenting cells 
(APCs) at the injection site. This mechanism is associated 
to the enrichment of activated dendritic cells within the 
regional draining lymph nodes (Leong et al 1999; Simons 
et al 1999; Wiseman et al 2001; Dranoff 2002; Yang et al 
2003; Reali et al 2005). This agent has been used in clini-
cal practice with different therapeutical objectives for a 
long time.
Etoposide (ETP) was the other agent selected. In experi-
mental tumor models, administration of low dosages of 
certain cytostatic drugs at the site of antigenic stimulation 
(tumor or vaccine) facilitates the development of strong anti-
tumoral T cell-immunity. T cell-suppressor depletion at the 
antigenic stimulation site and at the draining lymph nodes 
has been demonstrated as the locoregional mechanism of 
action for this immuno-potentiation. ETP, cisplatinum, and 
cyclophosphamide–active metabolites have been the main 
effective drugs in these local chemo-immunotherapeutic 
protocols (Scheper et al 1984; Tan et al 1986; Claessen 
et al 1989, 1991, 1992; Limpens, Garssen, Scheper et al 
1990; Limpens, Garssen, Germeraad et al 1990; Limpens 
and Scheper 1991). ETP, one of these drugs, is active at the 
inoculation site, does not require liver activation and the dos-
age that can be safely inoculated locally is well known.
In this study, we have explored GM-CSF and ETP as 
isolated or associated local adjuvants of a cancer vaccine, 
assuming that these agents can be complementary in the 
locoregional immunomodulation to enhance the systemic 
antitumoral protective immunity. Advanced ovarian can-
cer patients were the patient population studied. As can-
cer vaccine we have tested the autologous thermostable 
hemoderivative cancer vaccine (ATH-CV), a procedure 
with well-documented systemic effects of sensitization 
against vaccine antigens and antiprogressive activity upon 
tumor growth including ovarian cancer (Lasalvia, Cucchi, 
Carlevaro, et al 1995; Lasalvia, Cucchi, DeStefani et al 1995; 
Lasalvia et al 2003; Garcia-Giralt et al 2006; Lasalvia-Prisco 
et al 2006a, 2006b).
Patients and methods
Patients
The study was conducted in patients admitted to medical 
centers that submitted medical data to the Cooperative Trials 
Center (CTC) of PharmaBlood, R and D Department, Florida, 
USA (PharmaBlood is a non-pharmaceutical concerned 
company supporting scientiﬁ  c research in medical procedures 
using hemoderivatives).
Eligibility criteria
Patients who were enrolled in this open, randomized phase II 
study had to meet the following criteria: to have histologically 
or cytologically proven persistent or recurrent (relapse being 
observed within 1 year of the last platinum-based chemo-
therapy regimen) stage III or IV ovarian adenocarcinoma, 
excluding borderline tumor, low-potential tumors, squamous 
cell carcinoma, and granulosa-theca cell tumors (International 
Federation of Gynecology and Obstetrics); in demonstrated 
progression according to RECIST (Therasse et al 2000) cri-
teria with serum CA-125 level also progressing; and to have 
received at least one chemotherapeutic regimen, with the last 
regimen featuring platinum compounds at therapeutically 
adequate and potentially active doses. Patients must have at 
least one bidimensionally measurable lesion by computed 
tomography scan or magnetic resonance imaging, with at 
least one diameter greater than or equal to 2 cm. Patients had 
to be 18 years or older, they must have had a performance 
status of  2 on the Eastern Cooperative Oncology Group 
scale (Oken et al 1982) or  60% on the Karnofsky scale 
(Schag et al 1984) with an expected survival of at least 6 
months. Baseline blood laboratory assessment of organic 
functions was as follows: adequate bone marrow function: 
WBC   3000/mm3, ANC   1500/mm, Hgb   9.0 g/dl, and Biologics: Targets & Therapy 2007:1(2) 175
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platelets  100,000/ mm3; adequate liver function: bilirubin 
  1.5 mg/dl, AST   2; adequate kidney function: creatinine 
  1.5 mg/dl.
Written informed consent was obtained from each 
patient.
Exclusion criteria
Exclusion criteria included the following: brain or leptomen-
ingeal metastasis; previous or concurrent malignancies at 
other sites including abdominal adenocarcinoma of unknown 
origin and symptomatic peripheral neuropathy; patients with 
documented anaphylactic reaction to any drug, recognized 
immunodeﬁ  ciency disease or active autoimmune disease and 
those who have had previously immunotherapy of any type 
within the past 6 weeks or who were receiving treatment 
with immunosuppressive therapy. In addition, signiﬁ  cant 
cardiovascular abnormalities, active infection causing fever 
or other medical condition requiring speciﬁ  c treatment were 
within the exclusion criteria.
Clinical trial
The Institutional Review Board (IRB) approved the trial, 
which complied with the Declaration of Helsinki (World 
Medical Association, 2004, website at http://www.wma.
net/e/policy/b3.htm). It was a prospective, randomized, 
controlled trial; the treating physicians did not participate in 
the arm randomization for their patients that was performed 
remotely at the above-mentioned CTC. The patients were ran-
domized into 4 Groups that received different treatments. The 
trial duration for each patient was 6 months (180 trial days): 
1 month of pre-treatment background, 1 month of different 
treatments for each Group accomplishing the predetermined 
treatment schedule and 4 months of post-treatment follow-up 
after ﬁ  nishing treatments.
Treatments schedule
Patients assigned to Group 1 received the ATH-CV, as it was 
previously described (Lasalvia-Prisco et al 2003). Brieﬂ  y, 
ﬁ  ve days before the beginning of the treatment period (26th 
trial day), twenty milliliters of blood were drawn from the 
femoral artery in a tube containing 5000 IU heparin. The 
blood was allowed to sediment at 37 °C for 1 hour. Then, 
cellular lysis was produced by exposing the supernatant of 
plasma and cells to hypotonic shock with 3 volumes of dis-
tilled water for 15 min, and followed by freezing at −20 °C. 
After 24 hours, the preparation was thawed and incubated 
at 100 °C for 10 min. After ﬁ  nal ﬁ  ltration through a cellu-
lose acetate membrane ﬁ  lter (0.22 μm pore diameter), the 
preparation was divided into 5 vials: 1 test-vial containing 
0.5 ml and 4 vaccine-vials containing equal aliquots of the 
remaining preparation. All vials were stored at −20 °C until 
use. The 4 vaccine-vials were used on days 1, 14, 21, and 28 
of the treatment period (one month: 31st to 60th trial day).
Patients assigned to Group 2 received the same protocol 
than Group 1 but GM-CSF 300 micrograms were injected 
in the vaccination sites simultaneously with each vaccine 
following the chronology Vaccine-Adjuvant selected for 
GM-CSF in previous reports (Disis et al 1996).
Patients assigned to Group 3 received the same protocol 
than Group 1 plus ETP 10 mg/day injected at vaccination 
sites 1 to 4 days after each vaccine, following the chronol-
ogy Vaccine-Adjuvant selected for ETP in previous reports 
(Limpens, Garssen, Germeraad et al 1990).
Patients assigned to Group 4 received the same protocol 
than Group 1 but GM-CSF 300 micrograms were injected in 
the vaccination sites simultaneously with each vaccine and 
ETP 10 mg/day was injected at vaccination sites 1 to 4 days 
after each vaccine.
Evaluations
The vaccine effect was assessed in each Group comparing 
the post-treatment versus the pre-treatment evaluations of 
parameters measuring the vaccine effects, in other words, 
each Group was its own control. Afterwards, the vaccine 
effects assessed in the different Groups including adjuvants 
(Groups 2, 3 and 4) were compared with the Group without 
the tested adjuvants (Group 1) in order to validate the adju-
vant activity.
Pre-treatment background evaluations
The following evaluations were performed before starting 
treatments:
1.  Tumor growth assessed in a measurable lesion image 
using VoluMeasure®, a volume-measurement application 
developed by Drs. Ge Wang, Jun Ni, and Simon Kao 
of the College of Medicine, University of Iowa. Tumor 
growth was calculated for each patient as the percent 
variation of measured tumor size at 1st and 30th trial 
days (same image technology for same lesion localization 
allowed comparative assessment).
2.  Thirty-day variation of CA-125, measured between the 
1st and 30th trial days.
3.  Delayed type hypersensitivity (DTH) test was performed at 
the 28th trial day in each patient with an aliquot of the autolo-
gous thermostable hemoderivative (ATH) lyophilized and 
recovered in 1/10 of initial volume (ATH × 10). DTH test Biologics: Targets & Therapy 2007:1(2) 176
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was read 48 hours after the intradermal inoculation (30th 
trial day) and it will be considered positive if it produced 
an induration  5 mm.
Post-treatment follow-up evaluation
The post-treatment assessments were:
1.  At day 30th after ﬁ  nishing treatments (90th trial day), 
DTH elicited by ATH × 10 was performed and the posi-
tive (induration  5 mm) or negative (induration   5 mm) 
was registered 48 hours after the test.
2.  At day 120th after ﬁ  nishing treatments (180th trial day), 
the previous 30-day increments of CA-125 and tumor 
growth were registered, as in the pre-treatment back-
ground evaluation, taking into account that in previous 
reports optimal tumor anti-progressive effect was demon-
strated 120 days after ATH vaccination (Lasalvia-Prisco 
et al 2003, 2006a, 2006b).
3.  At day 120th after ﬁ  nishing treatments (180th trial day), 
in each patient a SIN localization by technetium scintig-
raphy was performed as it was described (Cochran et al 
2000) and mainly used for melanoma SLN (Mariani et al 
2002). Afterwards, SIN was surgically removed and 
immunophenotyping of cell populations was processed 
by ﬂ  ow cytometry and immunocytochemistry, expanding 
the antibodies set as it was practiced to explore all relevant 
lymph node cell populations (Bryan et al 1993; Vuylsteke 
et al 2002). Brieﬂ  y, 0.4 ml of Technetium-99 m of unﬁ  l-
tered sulfur colloid (containing 37 MBq/ml, or 1 mCi/ml) 
was injected intradermally in the four quadrants (0.1 ml 
each) around the circumference of the vaccination site 
24 hours before the SIN removal. Dynamic sequences 
and static views with a gamma camera allowed the radi-
ologist to mark on the skin the SIN localization. Ten to 
ﬁ  fteen minutes before the surgery, 5 ml of 1% isosulfan 
blue dye were injected around the vaccination site. Local 
anesthesia was used for inguinal SIN removal and it was 
performed in the outpatient clinic. The incision was rou-
tinely 1 inch long. The surgeon using a sterile hand-held 
gamma probe conﬁ  rmed location of the SIN that was 
marked on the skin by the radiologist, detecting the blue 
dye stained node. Patients consented to this procedure as 
part of the initial informed consent process for the trial. 
Immediately after removal, SINs were collected in sterile 
ice-cold complete medium, comprising IMDM supple-
mented with 25 mmol/L Hepes buffer with 10% fetal calf 
serum, 50 IU/ml penicillin-streptomycin, 1.6 mmol/L 
L-glutamine, and 0.05 mmol/L ß-mercaptoethanol 
Viable cells were isolated and analyzed using a scraping 
method. In short, SIN was bisected crosswise with a 
surgical scalpel and the cutting surface of the SIN was 
scraped 10 times with a surgical blade. SIN cells were 
rinsed from the blade with medium containing 0.1% 
DNase I, 0.14% collagenase A, and 5% fetal calf serum, 
incubated for 45 minutes at 37 °C, and subsequently in 
phosphate-buffered saline with 5 mmol/L ethylenedi-
amine tetraacetic acid for 10 minutes on ice. Finally, 
the SIN cells were washed twice in complete medium, 
counted, and directly stained with antibodies labeled with 
either phycoerythrin or ﬂ  uorescein isothiocyanate, and 
analyzed by ﬂ  ow cytometry at 10,000 or 100,000 events 
per measurement. In each case, the amount of antibody 
used was based on the manufacturer’s suggestion or 
titration experiments to optimize the signal/noise ratio. 
Immunocytochemistry was performed in cytospin prepa-
rations acetone-ﬁ  xed and stained immunocytochemically 
with different monoclonal antibodies. In preliminary 
studies, we have assessed a wide spectra of cell markers 
by ﬂ  ow cytometry and immunocytochemistry in order 
to identify the mobilized cell populations in immunized 
lymph nodes: CD1a, CD83 and CD86 for dendritic cells 
; CD9, CD10, CD14, CD19, CD20, CD21, CD24, CD38, 
CD40, CD45 and the surface Immunoglobulins IgG, 
IgM, IgA, IgD, kappa, lambda for B lymphocytes, CD3, 
CD4, CD5, CD8, and CD25 for T-lymphocytes (results 
not shown). According to these preliminary observations, 
mature dendritic cells (CD1a+/CD83+) and T-regulatory 
cells (CD4+/CD25+) were the marker sets deﬁ  ned in the 
frame of this study as the highly modiﬁ  ed cell popula-
tions in the examined lymph nodes of the four Groups of 
patients studied. Therefore, these cell populations were 
the target of the performed assessments (CD86 marker 
had the same variations as CD83+).
4.  During the 150 days after pre-treatment, toxicities were 
registered according to the Common Terminology 
Criteria for Adverse Events v3.0 or CTCAE (National 
Cancer Institute website at http://ctep.cancer.gov/forms/
CTCAEv3.pdf ).
5.  As it was incorporated in the informed consent, inde-
pendent and blinded reviewers performed assessment of 
each one of the CA-125, tumor growth, DTH tests and 
SIN immunophenotyping.
Statistical methods
The primary end-point of the study was SIN cell immu-
nophenotyping treatment-induced variations. Secondary 
efﬁ  cacy end-points included treatment-induced variations Biologics: Targets & Therapy 2007:1(2) 177
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of tumor growth, increments of CA-125 serum level and 
number of cases acquiring systemic sensitization to vaccine 
antigens (DTH).
The assessment of SIN cell immunophenotyping targeted 
cell populations: mature dendritic cells (CD1a+/CD83+) and 
T-reg cells (CD4+/CD25+) in Groups 2, 3 and 4 were com-
pared versus the respectively evaluations in Group 1 using 
the unpaired two-tailed Student t-test.
The assessment of tumor growth, CA-125 serum level 
increment and number of patients with positive DTH 
response was performed comparing the follow up evalua-
tions in each Group versus the respectively pre-treatment 
evaluations using the paired two-tailed Student t-test. The 
assessment of the differences between the post-treatment 
evaluations among the studied Groups was performed using 
the unpaired two-tailed Student t-test.
In all statistical assessments, p values   0.05 were 
considered signiﬁ  cant. Sample size was assessed to deter-
mine if it was sufﬁ  cient to attain a power of 80% with a 
signiﬁ  cance of 0.05.
Results
Figures 1 and 2 show mean and standard deviation of pre-
treatment and post-treatment evaluations of tumor growth 
and CA-125 serum level increment, respectively in each 
one of the 4 different treated Groups. In all groups, tumor 
growth decreased with statistical signiﬁ  cance after treatment: 
only vaccination (ATH-CV) (Figure 1, Group 1, p   0.05), 
vaccination (ATH-CV) plus GM-CSF as singular adjuvant 
(Figure 1, Group 2, p   0.02), vaccination (ATH-CV) plus 
ETP as singular adjuvant (Figure 1, Group 3, p   0.02) and 
vaccination (ATH-CV) plus both GM-CSF and ETP as double 
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Figure 1 Pre-treatment and post-treatment tumor growth: mean (± standard deviation) in the four 30-day differently treated groups. Upper Row – Pre-treatment: tumor size 
growth (RECIST) % in the 30 days previous to treatment start. Post-treatment: tumor size growth (RECIST) % in the 30 days between 120th and 150th day after ﬁ  nishing treat-
ment: Group 1:  ATH-CV. Pre-treatment 27.1 (±5.1); post-treatment 18.2 (±6.0); Group 2:  ATH-CV + GM-CSF. Pre-treatment 24.7 (±4.3); post-treatment 14.9 (±4.6); Group 3:  
ATH-CV + ETP treated. Pre-treatment 28.2 (±6.1); post-treatment 16.7 (±2.7) and Group 4:  ATH-CV + GM-CSF + ETP treated. Pre-treatment 25.6 (±4.4); post-treatment 10.0 
(±3.1). Lower Row – Linear increase in tumor size in all groups and in pre and post-treatment. The treatments slowed the tumor growth but did not stop it.Biologics: Targets & Therapy 2007:1(2) 178
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adjuvants (Figure 1, Group 4, p   0.005). The increase of 
CA-125 serum level was also lower in the post-treatment 
of the four Groups: only vaccination (ATH-CV) (Figure 2, 
Group 1, p   0.04), vaccination (ATH-CV) plus GM-CSF as 
singular adjuvant (Figure 2, Group 2, p   0.01), vaccination 
(ATH-CV) plus ETP as singular adjuvant (Figure 2, Group 3, 
p   0.01) and vaccination (ATH-CV) plus both GM-CSF and 
ETP as double adjuvants (Figure 2, Group 4, p   0.001).
Figure 3 shows DTH test against the vaccine immu-
nogen ATH (negative before treatment). The number of 
positive–tests elicited by ATH-CV (Group 1) was signiﬁ  -
cantly increased by GM-CSF (Group 2 vs Group 1: p   0.04), 
by ETP (Group 3 vs Group 1: p   0.04) and with higher 
signiﬁ  cance by both GM-CSF and ETP (Group 4 vs Group 
1: p   0.001).
Table 1 shows the signiﬁ  cant differences that were iden-
tiﬁ  ed in the immunophenotyped cell populations recovered 
from the vaccination site draining lymph nodes when the 
four Groups were compared: the mature dendritic cells 
(C1a+CD83+) and the T-regulatory cells (CD4+CD25+). For 
the mature dendritic cells, a marker of activated antigen 
presenting cells, the number identiﬁ  ed at the end of post-
treatment follow-up was signiﬁ  cant higher in Group 4 and 
Group 2 than in Group 1 and Group 3. For the T-Regulatory 
cells (T-Reg), a marker of SIN tolerogenic activity, the cell 
population in lymph nodes was signiﬁ  cant lower in Group 
4 and Group 3 than in Group 1 and Group 2.
In all four groups studied, no signiﬁ  cant toxicity (CTCAE 
higher than 2) was registered. No patients refused the SIN 
biopsy. There were no infections or complications at these 
surgical sites. In Table 1, the other cell-populations’ immu-
nophenotypes evaluated in preliminary studies were also 
indicated. For these cell populations, any statistic difference 
among the four Groups was evidenced in the frame of this 
study.
Discussion
When patients were treated with ATH-CV (Group 1), the 
post-treatment observations were a slow down of tumor 
growth (Figure 1), a decrease of CA-125 serum level incre-
ment (Figure 2) and an increase of the number of cases 
sensitized to the ATH-CV immunogen (Figure 3). These 
facts conﬁ  rmed the previously reported antiprogressive and 
immunogenic effects of this vaccine (Lasalvia-Prisco et al 
2006a, 2006b) supporting the development of the ATH-CV 
procedure as immunotherapy in advanced ovarian cancer.
Both, the GM-CSF (Group 2) and ETP (Group 3) admin-
istered locally as singular ATH-CV adjuvant enhanced the 
vaccine immunotherapy activity measured as: slow down of 
pre-treatment tumor growth (Figure 1), decrease of CA-125 
serum level increment (Figure 2) or increase of the number 
of positive DTH tests (Figure 3). Therefore, GM-CSF and 
ETP can be deﬁ  ned as local vaccine adjuvants for ATH-CV 
in advanced ovarian cancer. The use of both adjuvants, 
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Figure 2 Pre-treatment and post-treatment CA-125 serum level increase. Mean (± standard deviation) in the four 30-day differently treated groups. Pre-treatment: Increase 
of CA-125 in the 30 days previous to treatment start. Post-treatment: Increase of CA-125 in the 30 days between 120th and 150th day after ﬁ  nishing treatment. Treatments 
and results: Group 1:  ATH-CV. Pre-treatment 138.6 (±6.1); post-treatment 103.9 (±4.6). Group 2:  ATH-CV + GM-CSF. Pre-treatment 136.3 (±5.8); post-treatment 78.3 
(±5.2). Group 3:  ATH-CV + ETP treated. Pre-treatment 140.5 (±7.1); post-treatment 80.1 (±6.7). Group 4:  ATH-CV + GM-CSF + ETP treated. Pre-treatment 139.6 (±5.9); 
post-treatment 54.2 (±4.1).Biologics: Targets & Therapy 2007:1(2) 179
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GM-CSF and ETP, jointly administered with ATH-CV 
(Group 4) produced stronger effects than the use of each one 
separately (Figures 1, 2, and 3), evidencing the cumulative 
adjuvant effect of these two agents for this model. Immu-
nophenotyping studies of draining lymph nodes (Table 1) 
suggest as mechanism of action for the tested vaccine adju-
vants their known effects upon the immunity committed cell 
populations at SIN level: GM-CSF recruits and activates 
the antigen presenting cells increasing the locoregional 
presence of mature dendritic cells (Molenkamp et al 2005) 
and ETP produces a locoregional depletion of suppressor 
cells (Limpens and Scheper 1991) today speciﬁ  cally identi-
ﬁ  ed as the tolerogenic lymphocyte population of T-reg cells 
or CD4+CD25+ (Battaglia et al 2003; Viguier et al 2004). 
In melanoma patients, it was reported that mature dendritic 
cells (CD1a+CD83+) induce T-cell activation under pro-
inﬂ  ammatory conditions. Mature Dendritic cells also increase 
signiﬁ  cantly their frequency in the SLN after intradermal 
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Figure 3 Delayed type hypersensitivity (DTH) positive ( 5 mm) and negative ( 5 mm) elicited by the vaccine autologous thermostable hemoderivative cancer vaccine 
(ATH-CV) after vaccination with: ATH-CV (Group 1); ATH-CV plus different vaccine adjuvants: GM-CSF (Group 2), ETP (Group 3) and GM-CSF + ETP (Group 4).
Table 1 Among the cell populations recovered from draining lymph nodes of vaccination sites and immunophenotyped, this table 
shows the cell populations with statistical signiﬁ  cant differences when the four differently treated Groups were compared. Group 1 
(ATH-CV): Autologous Thermostable Hemoderivative-Cancer Vaccine; Group 2 (ATH-CV + GM-CSF): Granulocyte Macrophage-
Colony Stimulant Factor as local adjuvant of ATH-CV; Group 3 (ATH-CV + ETP): Etoposide as local adjuvant of ATH-CV; Group 4 
(ATH-CV + GM-CSF + ETP) Granulocyte Macrophage-Colony Stimulant Factor plus Etoposide as local adjuvants of ATH-CV.
  Group 1 (**)    Group 2 (**)  Group 2   Group 3 (**)  Group 3  Group 4 (**)  Group 4 
        vs     vs     vs
        Group  1     Group  1     Group  1
  Mean S.D.   Mean S.D. p  Mean S.D. p  Mean S.D. p
CD1a+ CD83+ (*)
Number by 600 CD3 +T cells  7.4  1.8  11.6  2.1   0.02 7.5  1.6   0.9 11.8 2.0  0.02
CD4+ CD25+ (*)
% of CD4+ T cells  9.2  1.1  9.0  1.2   0.9 3.4  1.1  0.03 3.2  0.8   0.02
*Immunophenotyping
CD1a+ CD83+ : Mature dendritic cells
CD4+ CD25+ : T-Regulatory cells
**Treatments
Group 1: ATH-CV
Group 2: ATH-CV + GM-CSF
Group 3: ATH-CV + ETP
Group 4: ATH-CV + GM-CSF + ETP
The following immunophenotypes were assessed. CD1; CD2; CD3; CD4; CD5; CD8; CD9; CD10; CD13; CD14; CD19; CD20; CD21; CD22; CD24; CD33; CD38; CD43; 
CD45; CD56; CD71; CD83; bcl-2; CD1a; CD25. No other set than CD1a+ CD83+ cells and CD4+ CD25+ showed any statistical difference among the tested Groups. At the 
dose used, Etoposide did not produce the known cytotoxic effects upon other lymphocyte as CD3+ or CD8+. The dendritic marker CD86+ considering its variation similar 
to CD83+ in this model, was not tested.Biologics: Targets & Therapy 2007:1(2) 180
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administration of GM-CSF at the melanoma excision site, 
as indicative of increased DC migration (Molenkamp et al 
2005).
Therefore, the role of GM-CSF as adjuvant of protective 
cancer vaccine effects at the local level could be an increase 
of T-cell activation at SIN level as result of the increased 
number of mature dendritic cells.
T-reg cells are well identiﬁ  ed as tolerogenic circulant cells 
in cancer patients and it was conﬁ  rmed that CD4+CD25+ cells 
are involved in the control of the local immune response in 
human lymph node metastatic melanoma. Their frequency is 
clearly increased in metastatic lymph nodes (SLN) compared 
with tumor-free satellite lymph nodes. The CD4+CD25+, 
lymph node occupants, inhibit in vitro the proliferation 
and cytokine production of autologous tumor inﬁ  ltrating 
CD4+CD25– as well as CD8+ T cells in a cell-contact-depen-
dent manner (Viguier et al 2004). Therefore, decreasing the 
number of CD4+CD25+ in SIN is a contribution of the Eto-
poside Adjuvancy to enhance the local protective immune 
responses in vaccinated lymph nodes. The expression of 
FOXP3 and the functional analysis of the in vitro or in vivo 
immune-inhibitory activity of these CD4+CD25+ cells could 
conﬁ  rm the T-Reg phenotype of these cells but the found 
variation of the CD+CD25+ population is compatible with 
the immune conditioning proposed.
This double and complementary immunomodulation of 
SIN cell populations elicits a SIN microenvironment condi-
tioned to produce a locoregional immune response protective 
or immunogenic, minimizing the option of permissive or 
tolerogenic immune responses.
As it was mentioned, this locoregional immune response 
against the vaccine TAA conﬁ  gured at vaccination site 
draining lymph node or SIN is decisional because it starts a 
systemic immune response with the same conﬁ  guration as its 
own. Therefore, immune effectors cells with predominantly 
protective or anti-tumoral activity will be found as circulant 
cells, lymph organ cells and tissue inﬁ  ltrative cells. The 
remote effects upon tumor growth and DTH test are evidence 
of this systemic immune effector activity.
The GM-CSF and ETP, as complementary local adju-
vants of the tested cancer vaccine, promote the vaccination 
site and SIN as a biological start-engine of a systemic 
protective-immune-response that could be denominated 
immunotherapeutic site (ITS). As consequence, the vaccina-
tion could counteract the biological start-engine of a permissive 
tolerogenic microenvironment conﬁ  gured by the SLN-condi-
tioned by tumor cytokines during the natural history of malig-
nancy (Cochran et al 2006).
This counteraction between the permissive tumor 
immunomodulation and the vaccine plus adjuvant protec-
tive immunomodulation must be optimized through future 
research of more powerful adjuvant systems, maintaining 
the safety of the double adjuvancy GM-CSF + ETP that was 
evidenced in this study, where no relevant clinical toxicity 
or side effects were registered.
Conclusions
In advanced ovarian cancer, the vaccination site in ATH-CV 
can be used to access SIN safely with vaccine adjuvants 
as GM-CSF and ETP in order to elicit an immunomodula-
tion of the locoregional immunity and to start a systemic 
immune response predominantly protective or antitumoral. 
In the tested conditions and during the observation period, 
all tumors continued growing but a slower rate of tumor 
growth was observed. To optimize this antitumoral effect 
will be the goal of future studies. At the basic level, further 
research of cell functionality of SIN is warranted. At the 
clinical level, if other cancer vaccines could obtain beneﬁ  ts 
from the association of these adjuvants, if other adjuvant 
designs could optimize these results and if the same results 
could be reproduced using this immunotherapy procedure in 
other malignancies also must be investigated.
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